Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 29 publications
The role of RAD23A in DNA repair and proteasome-dependent protein degradation in multiple myeloma.
Journal: Blood cancer journal
Published: April 09, 2026
Proteasome Subunit PSMD1 is a Key Therapeutic Target in Multiple Myeloma.
Journal: Blood
Published: March 26, 2025
Proteasome subunit PSMD1 is a key therapeutic target in multiple myeloma.
Journal: Blood
Published: March 26, 2025
A BCMA-mRNA vaccine is a promising therapeutic for multiple myeloma.
Journal: Blood
Published: January 27, 2025
Correction: BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: July 03, 2024
Loss of GABARAP mediates resistance to immunogenic chemotherapy in multiple myeloma.
Journal: Blood
Published: October 04, 2023
BCMA-targeted bortezomib nanotherapy improves therapeutic efficacy, overcomes resistance, and modulates the immune microenvironment in multiple myeloma.
Journal: Blood cancer journal
Published: August 05, 2023
Epigenetic regulation of CD38/CD48 by KDM6A mediates NK cell response in multiple myeloma.
Journal: Nature communications
Published: July 17, 2023
Development of a Covalent Inhibitor of c-Jun N-Terminal Protein Kinase (JNK) 2/3 with Selectivity over JNK1.
Journal: Journal of medicinal chemistry
Published: February 24, 2023
BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: November 25, 2022
γ-secretase inhibitors augment efficacy of BCMA-targeting bispecific antibodies against multiple myeloma cells without impairing T-cell activation and differentiation.
Journal: Blood cancer journal
Published: May 17, 2022
Last Updated: 09/26/2026